Advancement in Acute Myeloid Leukemia Treatment: Kura Oncology Initiates Phase 1 KOMET-008 Trial with Ziftomenib in Combination Therapies Overview Kura Oncology, Inc., a company leading the way in precision medicine for cancer, has begun a promising new clinical trial for Acute Myeloid Leukemia (AML) treatment. Clinical Trial Details Company: Kura Oncology, Inc. Indication: Acute Myeloid Leukemi..
Jubilant Therapeutics, a precision oncology and immunology-focused biotech, is set to begin Phase II and first-in-human trials in 2023 with two Orphan Drug Designations. Their pipeline is generated entirely in-house using their unique discovery engine called the Therapeutic Index and Brain Exposure Optimization (TIBEO) which identifies candidate molecules with enhanced therapeutic indices that c..
Jubilant Therapeutics is gearing up for Phase II and first-in-human trials in 2023 with its pipeline of precision medicines that offer safety and therapeutic advantages in cancer and immunology. The company's drug discovery approach focuses on developing candidates through clinical proof of concept, partnering those assets with companies to advance them through late-stage clinical development an..
